InflaRx 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Okay. Good morning, everyone. Welcome to Guggenheim's 3rd Annual Healthcare Innovation Conference. My name is Yatin Suneja, one of the senior biotech analysts here at the firm. It is my pleasure to welcome our next presenting company, InflaRx. We have executives here from the team. We have CEO and founder Niels Riedemann. We have Chief Financial Officer Thomas Taapken, and we also have here with us VP and Head of IR, Jan Medina. Gentlemen, thank you so much for your time. Niels, why don't you make some opening comments? You just hosted a capital market day, provided a lot of update. Perhaps maybe touch a little bit on the key highlights, and then we'll go a little bit more into the depth of the discussion after you make some comments.
Yes, absolutely. Happy to do so. First of all, thanks for inviting us, Yatin. Always a pleasure to be here. We just hosted a capital markets day. We are very excited about moving our molecule, izicopan, an oral C5aR inhibitor, which we believe has best-in-class potential into the renal space, particularly in ANCA vasculitis and beyond. We have starting trials here in ANCA vasculitis, a larger one that will be placebo-controlled. Maybe we talk about that a bit more in detail. That's really designed to show efficacy of the molecule on top of standard of care, and also designed to hone in on a signal, particularly on the renal signal. We will kick this off as soon as possible. It's in the making, and it's been informed by initial interactions with the regulators here in this country, with the FDA.
At the same time, we're trying to kick off another study in ANCA vasculitis, which is really more proving the point that you can rapidly replace or completely replace corticosteroids in this disease, which remains one of the key high unmet medical needs. Patients, likewise, as also physicians that we speak to, really mention that that was one of the key advantages the current molecule of avacopan, the approved molecule in this country, has been delivered to patients. We're excited about that because we don't want to drop the ball on this particular aspect. We're getting inbounds from vasculitis foundations in Europe, in the U.S., and elsewhere, really showcasing that this is meaningful to patients.
So, this is also a bit meaningful because we're running with our molecule, and our partner in China, Staidson, is running with the antibody that targets the ligand C5a, is running a phase III with a complete replacement strategy. It's the first trial ever to show that you can replace corticosteroids completely. It's designed for non-inferiority, and it's been informed by discussions with the Chinese regulators that agreed on a non-inferiority design for approval. That's exciting, those data coming in 2028. The open-label data will also, first data coming in in 2028. That would be a very important signal for us. We're also excited beyond. We have a starting study in aHUS. This will be a small study.
It's really with a key center that is a referral center for this disease and has ample knowledge on the complement pathways and really is interested in this trial that we believe really has the potential for a true paradigm shift in the field, and here's why. A lot of people believe that because the drugs like eculizumab, ravulizumab, were the first approvals in this field, had such success that there must be a MAC component, a membrane attack complex component, which, as you know, our drug doesn't touch. We have evidence from research, and others have gathered evidence as well, that the key driver of this disease that evokes this thrombotic microangiopathy, the endothelial damage, is actually likely to be driven by C5a, C5aR. So we're trying to see whether that can be done. If so, it could introduce a true paradigm shift.
People would see that this pathway is very meaningful. Plus, keep in mind, we don't vaccinate patients. We don't see a much higher infection rate with the ligand antibody where we have ample experience, even long-term dosing. That could be huge advantages. At the same time, it's an oral, so that's also for the field important. Even though very small, we may have first patient data to be reported already in 2027. We believe this is interesting also to be mentioning that this is an open-label trial, but this is also open-label situations for approval. So really very rare, very interesting, high-price drug disease area with still unmet need, and the pathway could go into an open-label approval trial later if that works.
Got it. Last but not least, a basket study in IgAN and IgAN RPGN, really to increase probability of success, to show the drug is active in this disease.
This will be an open-label study. We will have data coming there already in 2028, initial data, and we think that will further the interest in this molecule in the broader renal space. We also may add another indication. We haven't disclosed that yet, but we're finalizing work on that as well.
Got it. At a high level, what is the development? I mean, it seems like the development strategy is to basically go as broad and capture all of the renal indication that is possible. Would you go beyond the renal areas, or that sort of is the key focus right now?
This is the key focus right now. We have very strong conviction that this molecule is active in other areas in the broader I&I space, like in Hidradenitis suppurativa, where we had first data, or even in the space like CSU, which still, these are still chronic spontaneous urticaria, which are still disease areas of unmet need, I would say. There's still improvements to be done. But we focus on renal. The strategy really is to deliver as fast as we can and attempt to market with the C5aR in ANCA vasculitis. That's the key focus because that's where the value is. We are still in discussions with regulators. We're considering path where we can expedite the path to a registrational study.
Our entire strategy is geared towards being as fast as possible, but at the same time, you cannot shortcut certain requirements that the regulators just have.
Sure, I understand. Let's maybe remind our audience the properties of izicopan. How is that differentiated versus avacopan and what you have seen at preclinical level, then healthy volunteer level, then at clinical level?
So the original idea to design this, and our team, Ren Guo, the other founder, our CSO, and his team worked for years on this, was the interesting part that ChemoCentryx back then had found a binding site, an allosteric binding site that seemed to be delivering a very potent blocking of the molecule. We thought that there's a real opportunity because we saw the human data. So while in vitro this molecule is very potent, we saw this opportunity to have a much better PK.
Yeah And a better formulation.
So originally, we started all the work to say, "We want to make use of the knowledge, but we want to design a better molecule that reaches fast and higher PK," because we believe that, A, in many of the diseases, it's important that your drug is fast-acting, and B, with having a higher coverage of the signal right away, we believe it will translate into more efficacy. In head-to-head preclinical studies, inflammatory studies, we've already shown almost a doubling of efficacy at the exact same dose, so there's evidence that that may be playing out in humans as well. We then learned that by working on this and introducing this trifluoromethyl group, we also seem to have a much better safety.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
